

Contents

Preface	xi
 PART I PRELIMINARIES	
 1 Introduction	 3
1.1 What are Clinical Trials?, 3	
1.2 History of Clinical Trials, 4	
1.3 Regulatory Process and Requirements, 10	
1.4 Investigational New Drug Application, 17	
1.5 New Drug Application, 24	
1.6 Clinical Development and Practice, 31	
1.7 AIMS and Structure of the Book, 42	
 2 Basic Statistical Concepts	 45
2.1 Introduction, 45	
2.2 Uncertainty and Probability, 46	
2.3 Bias and Variability, 49	
2.4 Confounding and Interaction, 57	
2.5 Descriptive and Inferential Statistics, 66	
2.6 Hypotheses Testing and p -Values, 68	
2.7 Clinical Significance and Clinical Equivalence, 75	
2.8 Reproducibility and Generalizability, 79	
 3 Basic Design Considerations	 85
3.1 Introduction, 85	
3.2 Goals of Clinical Trials, 86	
3.3 Target Population and Patient Selection, 90	
3.4 Selection of Controls, 97	
3.5 Statistical Considerations, 105	

3.6	Other Issues, 112	
3.7	Discussion, 115	
4	Randomization and Blinding	117
4.1	Introduction, 117	
4.2	Randomization Models, 118	
4.3	Randomization Methods, 124	
4.4	Implementation of Randomization, 144	
4.5	Generalization of Controlled Randomized Trials, 149	
4.6	Blinding, 153	
4.7	Discussion, 160	
 PART II DESIGNS AND THEIR CLASSIFICATIONS		
5	Designs for Clinical Trials	165
5.1	Introduction, 165	
5.2	Parallel Group Designs, 167	
5.3	Clustered Randomized Designs, 172	
5.4	Crossover Designs, 177	
5.5	Titration Designs, 185	
5.6	Enrichment Designs, 191	
5.7	Group Sequential Designs, 195	
5.8	Placebo-Challenging Designs, 197	
5.9	Blinded Reader Designs, 203	
5.10	Discussion, 207	
6	Designs for Cancer Clinical Trials	211
6.1	Introduction, 211	
6.2	General Considerations for Phase I Cancer Clinical Trials, 213	
6.3	Single-Stage Up-and-Down Phase I Designs, 214	
6.4	Two-Stage Up-and-Down Phase I Designs, 217	
6.5	Continual Reassessment Method Phase I Designs, 219	
6.6	Optimal and Flexible Multiple-Stage Designs, 222	
6.7	Randomized Phase II Designs, 229	
6.8	Discussion, 232	
7	Classification of Clinical Trials	237
7.1	Introduction, 237	
7.2	Multicenter Trials, 238	
7.3	Superiority Trials, 245	
7.4	Active Control and Equivalence/Noninferiority Trials, 248	

- 7.5 Dose–Response Trials, 261
- 7.6 Combination Trials, 266
- 7.7 Bridging Studies and Global Trials, 278
- 7.8 Vaccine Clinical Trials, 285
- 7.9 QT Studies, 291
- 7.10 Discussion, 299

PART III ANALYSIS OF CLINICAL DATA

- 8 Analysis of Continuous Data 305**
 - 8.1 Introduction, 305
 - 8.2 Estimation, 306
 - 8.3 Test Statistics, 310
 - 8.4 Analysis of Variance, 316
 - 8.5 Analysis of Covariance, 323
 - 8.6 Nonparametric Methods, 325
 - 8.7 Repeated Measures, 332
 - 8.8 Discussion, 341
- 9 Analysis of Categorical Data 343**
 - 9.1 Introduction, 343
 - 9.2 Statistical Inference for One Sample, 345
 - 9.3 Inference of Independent Samples, 358
 - 9.4 Ordered Categorical Data, 364
 - 9.5 Combining Categorical Data, 368
 - 9.6 Model-Based Methods, 374
 - 9.7 Repeated Categorical Data, 382
 - 9.8 Discussion, 387
- 10 Censored Data and Interim Analysis 389**
 - 10.1 Introduction, 389
 - 10.2 Estimation of the Survival Function, 391
 - 10.3 Comparison Between Survival Functions, 399
 - 10.4 Cox’s Proportional Hazard Model, 405
 - 10.5 Calendar Time and Information Time, 419
 - 10.6 Group Sequential Methods, 424
 - 10.7 Discussion, 438
- 11 Sample Size Determination 441**
 - 11.1 Introduction, 441
 - 11.2 Basic Concept, 442

- 11.3 Two Samples, 447
- 11.4 Multiple Samples, 456
- 11.5 Censored Data, 459
- 11.6 Dose–Response Studies, 464
- 11.7 Crossover Designs, 471
- 11.8 Equivalence and Noninferiority Trials, 481
- 11.9 Multiple-Stage Design in Cancer Trials, 490
- 11.10 Multinational Trials, 490
- 11.11 Comparing Variabilities, 500
- 11.12 Discussion, 517

PART IV ISSUES IN EVALUATION

12 Issues in Efficacy Evaluation 521

- 12.1 Introduction, 521
- 12.2 Baseline Comparison, 523
- 12.3 Intention-to-Treat Principle and Efficacy Analysis, 528
- 12.4 Adjustment for Covariates, 536
- 12.5 Multicenter Trials, 541
- 12.6 Multiplicity, 548
- 12.7 Data Monitoring, 558
- 12.8 Use of Genetic Information for Evaluation of Efficacy, 564
- 12.9 Sample Size Reestimation, 570
- 12.10 Discussion, 572

13 Safety Assessment 573

- 13.1 Introduction, 573
- 13.2 Extent of Exposure, 574
- 13.3 Coding of Adverse Events, 582
- 13.4 Analysis of Adverse Events, 595
- 13.5 Analysis of Laboratory Data, 602
- 13.6 Analysis of QT/QTc Prolongation, 610
- 13.7 Discussion, 615

PART V RECENT DEVELOPMENT

14 Biomarkers and Targeted Clinical Trials 619

- 14.1 Introduction, 619
- 14.2 Concepts and Strategies, 620

14.3	Biomarker Development and Validation, 623	
14.4	Designs of Targeted Clinical Trials, 630	
14.5	Analyses of Targeted Clinical Trials, 640	
14.6	Discussion, 647	
15	Trials for Evaluating Accuracy of Diagnostic Devices	649
15.1	Introduction, 649	
15.2	Study Design, 651	
15.3	Measures of Diagnostic Accuracy, 656	
15.4	Reporting Results, 663	
15.5	Sample Size Estimation, 672	
15.6	Discussion, 675	
16	Statistical Methods in Translational Medicine	677
16.1	Introduction, 677	
16.2	Biomarker Development, 678	
16.3	Bench-to-Bedside, 682	
16.4	Animal Model Versus Human Model, 689	
16.5	Translation in Study Endpoints, 691	
16.6	Bridging Studies, 696	
16.7	Discussion, 699	
16.8	Appendix, 700	
17	Adaptive Clinical Trial Designs	703
17.1	Introduction, 703	
17.2	What Is Adaptive Design?, 704	
17.3	Well-Understood and Less Well-Understood Designs, 709	
17.4	Clinical/Statistical and Regulatory Perspectives, 713	
17.5	Impact of Protocol Amendments, 716	
17.6	Challenges in By-Design Adaptations, 721	
17.7	Obstacles of Retrospective Adaptations, 727	
17.8	Discussion, 729	
18	Traditional Chinese Medicine	733
18.1	Introduction, 733	
18.2	Fundamental Differences, 734	
18.3	Basic Considerations of TCM Clinical Trials, 741	
18.4	Other Issues in TCM Research and Development, 744	
18.5	Consortium for Globalization of Traditional Chinese Medicine, 751	
18.6	Discussion, 752	

PART VI CONDUCT OF CLINICAL TRIALS

19	Preparation and Implementation of a Clinical Protocol	755
19.1	Introduction, 755	
19.2	Structure and Components of a Protocol, 756	
19.3	Points to be Considered and Common Pitfalls During Development and Preparation of a Protocol, 762	
19.4	Common Departures for Implementation of a Protocol, 765	
19.5	Monitoring, Audit, and Inspection, 771	
19.6	Quality Assessment of a Clinical Trial, 775	
19.7	Discussion, 777	
20	Data Management of a Clinical Trial	779
20.1	Introduction, 779	
20.2	Regulatory Requirements, 781	
20.3	Development of Case Report Forms, 783	
20.4	Database Development, 787	
20.5	Data Entry, Query, and Correction, 788	
20.6	Data Validation and Quality, 791	
20.7	Database Lock, Archive, and Transfer, 792	
20.8	Critical Issues, 795	
	References	799
	Appendix A	845
	Index	851